Exelixis Inc. diskutieren
Exelixis Inc.
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
35,27 €
0,11 %
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at HC Wainwright from $29.00 to $40.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Piper Sandler from $36.00 to $37.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Truist Financial Co. from $38.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Oppenheimer Holdings Inc. from $38.00 to $41.00. They now have an "outperform" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $40.00 price target on the stock, up previously from $30.00.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Truist Financial Co. from $42.00 to $43.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Piper Sandler from $37.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $42.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Citigroup Inc. from $38.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $38.00 to $40.00. They now have an "outperform" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $40.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Citigroup Inc. from $45.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Truist Financial Corporation. They now have a $55.00 price target on the stock, up previously from $43.00.
Ratings data for EXEL provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Hasbro Inc. diskutieren